Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: PARP inhibitor 2X-121
Sponsor: Allarity Therapeutics
Collaborators: Smerud Medical Research International AS|Danish Breast Cancer Cooperative Group